Roseotoxin B alleviates cholestatic liver fibrosis through inhibiting PDGF-B/PDGFR-β pathway in hepatic stellate cells
@article{Wang2020RoseotoxinBA, title={Roseotoxin B alleviates cholestatic liver fibrosis through inhibiting PDGF-B/PDGFR-$\beta$ pathway in hepatic stellate cells}, author={Xingqi Wang and Yu-zhi Gao and Yu Li and Yuqing Huang and Yawen Zhu and Wei Lv and R Wang and Lingshan Gou and Chao Cheng and Zhaojun Feng and Jun Xie and Jun Tian and Ruiqin Yao}, journal={Cell Death \& Disease}, year={2020}, volume={11} }
Identifying effective anti-fibrotic therapies is a major clinical need that remains unmet. In the present study, roseotoxin B was shown to possess an improving effect on cholestatic liver fibrosis in bile duct–ligated mice, as proved by histochemical and immunohistochemical staining, hepatic biochemical parameters, and TUNEL apoptotic cell detection in tissue sections. Using cellular thermal shift assay, computational molecular docking, microscale thermophoresis technology, and surface plasmon…
18 Citations
Cynarin inhibits PDGF-BB-induced proliferation and activation in hepatic stellate cells through PPARγ
- Biology, ChemistryOpen Chemistry
- 2022
Abstract Cynarin, a caffeoylquinic acid compound that was mainly extracted from Cynara scolymus L., displays various activities such as antioxidant, antibacterial, choleretic, and hepatoprotective…
Therapy that Targets Growth Factor Receptors: Novel Approach for Liver Cirrhosis Treatment
- Medicine, Biology
- 2021
This chapter represents the evidences of the efficacy of growth factor receptors signaling downregulation for the suppression of liver fibrosis and cirrhosis and their individual manifestations.
miR-488-5p mitigates hepatic stellate cell activation and hepatic fibrosis via suppressing TET3 expression
- Biology, ChemistryHepatology International
- 2022
It is highlighted that miR-488-5p restrains the activation of HSCs and hepatic fibrosis via targeting TET3 which is involved in the TGF-β/Smad2/3 signaling pathway.
Progress in research on the roles of TGR5 receptor in liver diseases
- Biology, MedicineScandinavian journal of gastroenterology
- 2021
The discovery of the regulatory relationship between the TGR5 receptor and miRNA-26a provides a new direction for further studies of the molecular mechanism underlying the effects of TGR7, and could have therapeutic implications for various liver diseases.
Ghrelin ameliorates transformation of hepatic ischemia-reperfusion injury to liver fibrosis by blocking Smad and ERK signalling pathways, and promoting anti-inflammation and anti-oxidation effects.
- Biology, MedicineTransplant immunology
- 2022
Pathogenesis of Liver Fibrosis and Its TCM Therapeutic Perspectives
- Medicine, BiologyEvidence-based complementary and alternative medicine : eCAM
- 2022
The factors influencing liver fibrosis are described, focusing on the effects of cells, intestinal flora, iron death, signaling pathways, autophagy and angiogenesis on liver Fibrosis, and the therapeutic effects of herbal medicine on Liver fibrosis.
Identification of Liver Fibrosis-Related MicroRNAs in Human Primary Hepatic Stellate Cells Using High-Throughput Sequencing
- BiologyGenes
- 2022
The miRNAs identified may provide a basis and reference for the selection of diagnostic and therapeutic targets for hepatic fibrosis and the targeted genes were involved in collagen metabolism, extracellular matrix structural constituent, cytoskeletal protein binding, and cell adhesion.
Function of TREM1 and TREM2 in Liver-Related Diseases
- Medicine, BiologyCells
- 2020
The function of TREM1 and TREM2 in different liver diseases based on inflammation is reviewed, providing a more comprehensive perspective for the treatment of liver-related diseases.
RalA exerts an inhibitory effect on IL-1β/IL-18 secretion by blocking NLRP3 inflammasome activation in levornidazole-treated human THP-1 macrophages.
- BiologyInternational immunopharmacology
- 2020
The oncogenic potential of NANOG: An important cancer induction mediator
- BiologyJournal of cellular physiology
- 2020
It is intended to demonstrate that targeting NANOG can dimmish the CSCs, sensitize the tumor to chemotherapy, and eradicate the cancer cells.
References
SHOWING 1-10 OF 41 REFERENCES
The PDGF system and its antagonists in liver fibrosis.
- BiologyCytokine & growth factor reviews
- 2016
Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation.
- Biology, MedicineAmerican journal of physiology. Gastrointestinal and liver physiology
- 2018
The role of a classical modulator of hepatocellular apoptosis in early, cholestatic liver injury is explored and these include activation of NF-κB and MAPK signaling, production of inflammatory cytokines, and recruitment of neutrophils in response to Cholestasis.
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets
- Medicine, BiologyWorld journal of gastroenterology
- 2016
The role of HSCs in liver fibrosis is outlined and novel strategies to suppress HSC activity are details, thereby providing new insights into potential treatments for liver Fibrosis.
Hepatic stellate cells as key target in liver fibrosis.
- Biology, MedicineAdvanced drug delivery reviews
- 2017
Mechanisms of hepatic stellate cell activation
- Biology, MedicineNature Reviews Gastroenterology &Hepatology
- 2017
These findings reinforce the remarkable complexity and plasticity of HSC activation, and underscore the value of clarifying its regulation in hopes of advancing the development of novel diagnostics and therapies for liver disease.
Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents.
- Medicine, BiologyAdvanced drug delivery reviews
- 2017
Hepatocyte TNF Receptor–Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6–Linked Polyubiquitination of Apoptosis Signal‐Regulating Kinase 1
- Biology, Medicine
- 2020
It is demonstrated that tumor necrosis factor receptor–associated factor 6 (TRAF6) promotes lysine 6 (Lys6)‐linked polyubiquitination and subsequent activation of ASK1 to trigger the release of robust proinflammatory and profibrotic factors in hepatocytes, which, in turn, drive HSC activation and hepatic fibrosis.
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues.
- Biology, MedicineMolecular aspects of medicine
- 2019
Regulation of PDGF and its receptors in fibrotic diseases.
- Medicine, BiologyCytokine & growth factor reviews
- 2004
Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time
- Biology, MedicineInternational journal of molecular sciences
- 2019
Results showed that the anti-apoptotic effect of rh-HGF on hepatocytes coincided strikingly with the suppression of intrahepatic hemorrhage, and prothrombin time was considered to be the best parameter that correlated with the intrahePatic hemorrhages associated with hepatocellular damage.